4-(4-氨基苯氧基)-N-甲基-2-吡啶甲酰胺盐酸盐 | 911132-05-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-氨基苯氧基)-N-甲基-2-吡啶甲酰胺盐酸盐
• 英文名称: 4-(4-amino-phenoxy)-pyridine-2-carboxylic acid N-methylamide dihydrochloride
• 英文别名: 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide hydrochloride；4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide;hydrochloride
• CAS: 911132-05-3
• 化学式: C₁₃H₁₃N₃O₂*2ClH
• 分子量: 316.187
• InChiKey: FBISWECJLBBRLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.24
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  77.2
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  C₁₇H₂₂Cl₃N₃O₄ 、 4-(4-氨基苯氧基)-N-甲基-2-吡啶甲酰胺盐酸盐 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 21.17h， 生成 4-(2-{3-[4-(2-metylcarbamoyl-pyridin-4-yloxy)-phenyl]-ureido}-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  [EN] SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS
  [FR] DERIVES DE BISARYLUREE

  摘要：

  公开号：

  WO2005075425A3
• 作为产物：
  描述：

  对氨基苯酚 、 N-甲基-4-氯-2-吡啶甲酰胺 生成 4-(4-氨基苯氧基)-N-甲基-2-吡啶甲酰胺盐酸盐
  参考文献：
  名称：

  WO2006/105844

  摘要：

  公开号：

文献信息

• Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process
  申请人：Rao Dharmaraj Ramachandra

  公开号：US20100311980A1

  公开（公告）日：2010-12-09

  There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A) wherein R′ is selected from the group consisting of hydrogen, —C(O)OA, —C(O)CX 3 , —C(O)NH 2 , —C(O)—NHOH or There is also provided intermediate compounds of general formula (A), N-methyl-4-(4-ureidophenoxy)picolinamide, 4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenylcarbamate derivative and N-methyl-4-(4-(2,2,2-trihaloacetamido)phenoxy)picolinamide, processes for their preparation and their use in the preparation of sorafenib.

  提供了一种制备索拉非尼或其盐的方法，包括使用公式（A）的化合物，其中R′从氢、—C（O）OA、—C（O）CX3、—C（O）NH2、—C（O）—NHOH等组成的群体中选择。还提供了一般式（A）的中间化合物，N-甲基-4-(4-脲基苯氧基)吡啶酰胺，4-(2-(甲基氨甲酰)吡啶-4-氧基)苯基氨甲酸酯衍生物和N-甲基-4-(4-(2,2,2-三卤乙酰胺基)苯氧基)吡啶酰胺，以及它们的制备方法和在制备索拉非尼中的应用。
• [11C]Sorafenib: Radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice
  作者：Chiharu Asakawa、Masanao Ogawa、Katsushi Kumata、Masayuki Fujinaga、Koichi Kato、Tomoteru Yamasaki、Joji Yui、Kazunori Kawamura、Akiko Hatori、Toshimitsu Fukumura、Ming-Rong Zhang

  DOI：10.1016/j.bmcl.2011.03.002

  日期：2011.4

  Sorafenib (Nexavar, BAY43-9006, 1) is a second-generation, orally active multikinase inhibitor that is approved for the treatment of some cancers in patients. In this Letter, we developed [C-11] 1 as a novel positron emission tomography (PET) probe, and evaluated the influence of ABC transporters-mediated efflux on brain uptake using PET with [C-11] 1 in P-glycoprotein (P-gp)/breast cancer resistance protein (Bcrp) knockout mice versus wild-type mice. [C-11] 1 was synthesized by the reaction of hydrochloride of aniline 2 with [C-11] phosgene ([C-11] COCl2) to give isocyanate [C-11] 6, followed by reaction with another aniline 3. Small-animal PET study with [C-11] 1 indicated that the radioactivity level (AUC(0-60) (min), SUV x min) in the brains of P-gp/Bcrp knockout mice was about three times higher than in wild-type mice. (C) 2011 Elsevier Ltd. All rights reserved.